Major depressive disorder has been associated with activation of inflammatory processes as well as with reductions in innate, adaptive and non-specific immune responses. The objective of this study was to evaluate the association between major depression and a disease-relevant immunologic response, namely varicella-zoster virus (VZV)-specific immunity, in elderly adults. A cross-sectional cohort study was conducted in 104 elderly community dwelling adults P60 years of age who were enrolled in the depression substudy of the shingles prevention study, a double blind, placebo-controlled vaccine efficacy trial. Fifty-two subjects had a current major depressive disorder, and 52 age-and sex-matched controls had no history of depression or any mental illness. VZV-specific cell-mediated immunity (VZV-CMI) was measured by VZV responder cell frequency (VZV-RCF) and interferon-c enzyme-linked immunospot (ELI-SPOT) assays, and antibody to VZV was measured by an enzyme-linked immunosorbent assay against affinity-purified VZV glycoproteins (gpELISA). VZV-CMI, measured by VZV-RCF, was significantly lower in the depressed group than in the controls (p < 0.001), and VZV-RCF was inversely correlated with the severity of depressive symptoms in the depressed patients. In addition, an age-related reduction in VZV-RCF was observed in the depressed patients, but not in the controls. Furthermore, there was a trend for depressive symptom severity to be associated with lower ELISPOT counts. Finally, VZV-RCF was higher in depressed patients treated with antidepressant medications as compared to untreated depressed patients. Since lower levels of VZV-RCF appear to explain the increased risk and severity of herpes zoster observed in older adults, these findings suggest that, in addition to increasing age, depression may increase the risk and severity of herpes zoster.
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Introduction
Herpes zoster, or shingles, is a painful neurocutaneous syndrome caused by reactivation and replication of varicella-zoster virus (VZV) that has remained latent in sensory neurons following varicella (Gilden et al., 2000; Gnann and Whitley, 2002; HopeSimpson, 1965; Ragozzino et al., 1982) . The incidence and severity of herpes zoster increase with advancing age in association with a progressive age-related decline in VZV-specific T cell-mediated immunity (VZV-CMI) (Berger et al., 1981; Burke et al., 1982; Levin et al., 1992; Miller, 1980) . In the US, the incidence of herpes zoster exceeds 1% per year in persons P60 years of age; more than a million new cases occur each year; and one-third of the current population will experience herpes zoster during their lifetimenumbers destined to increase with the increasing age of the population (Donahue et al., 1995; Insinga et al., 2005; Oxman et al., 2005; Ragozzino et al., 1982) . VZV-CMI is thought to play a critical role in protecting against herpes zoster and postherpetic neuralgia, and we have found that the magnitude and duration of the boost in VZV-CMI induced by zoster vaccine parallels the clinical effects of the vaccine observed during a large scale efficacy trial, the shingles prevention study (SPS) (Levin et al., 2008; Oxman et al., 2005; Weinberg et al., 2009) . In contrast, antibody to VZV does not appear to protect against herpes zoster; levels of antibody to VZV do not decline with increasing age and higher levels of VZV-specific
